Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti- integrin agents

D. C. Calverley; G. J. Roth

doi:10.1016/S0889-8588(05)70051-4

Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti- integrin agents

D. C. Calverley, G. J. Roth

Research output: Contribution to journal › Article

11 Scopus citations

Abstract

Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.

Original language	English (US)
Pages (from-to)	1231-1249
Number of pages	19
Journal	Hematology/Oncology Clinics of North America
Volume	12
Issue number	6
DOIs	https://doi.org/10.1016/S0889-8588(05)70051-4
State	Published - Jan 1 1998

Fingerprint

ASJC Scopus subject areas

Hematology
Oncology

Cite this

Calverley, D. C., & Roth, G. J. (1998). Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti- integrin agents. Hematology/Oncology Clinics of North America, 12(6), 1231-1249. https://doi.org/10.1016/S0889-8588(05)70051-4

@article{2e6b9af2fc9a4f4e866c66441b7c33e0,

title = "Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti- integrin agents",

abstract = "Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.",

author = "Calverley, {D. C.} and Roth, {G. J.}",

year = "1998",

month = jan

day = "1",

doi = "10.1016/S0889-8588(05)70051-4",

language = "English (US)",

volume = "12",

pages = "1231--1249",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "6",

}

TY - JOUR

T1 - Antiplatelet therapy

T2 - Aspirin, ticlopidine/clopidogrel, and anti- integrin agents

AU - Calverley, D. C.

AU - Roth, G. J.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.

AB - Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.

UR - http://www.scopus.com/inward/record.url?scp=0032443790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032443790&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(05)70051-4

DO - 10.1016/S0889-8588(05)70051-4

M3 - Article

C2 - 9922934

AN - SCOPUS:0032443790

VL - 12

SP - 1231

EP - 1249

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -

Access to Document

10.1016/S0889-8588(05)70051-4